Future Biome

Cover Block

Attribute	Value
Name	Future Biome
Tagline	Developing precision fungal prebiotics for gut health and inflammatory disorders via B2B partnerships.
Founded	2022
Stage	Pre-Seed
Business Model	B2B
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	Latin America
Growth Profile	Venture Scale
Founding Team	Scientists and entrepreneurs [LinkedIn]
Funding Label	Undisclosed

Links

• Website: https://www.crunchbase.com/organization/future-biome
• LinkedIn: https://www.linkedin.com/company/future-biome

Executive Summary

Future Biome was a Latin American biotechnology venture that sought to commercialize precision fungal prebiotics, a novel approach to modulating the human microbiome for gut health and inflammatory disorders [Crunchbase]. Founded in 2022, the company's proposition centered on using artificial intelligence to predict and customize prebiotic efficacy based on individual microbiota enzyme profiles, aiming to move beyond generic fiber supplements to targeted, data-driven nutritional interventions [GRIDX] [BIO International Convention, 2026]. The founding team, led by CEO Soledad Gurovic, was composed of scientists and entrepreneurs [CB Insights] [LinkedIn].

Its business model was exclusively B2B, targeting licensing partnerships with healthcare providers, food supplement companies, and pharmaceutical firms [BIO International Convention, 2026]. The company secured undisclosed pre-seed funding from a syndicate of notable early-stage investors including Big Idea Ventures, LvlUp Ventures, and GRID EXPONENTIAL [Crunchbase]. Future Biome has ceased operations [Perplexity Sonar Pro Brief].

Data Accuracy: YELLOW -- Core product claims and investor list are corroborated by multiple databases; operational status is based on a single, informal source.

Taxonomy Snapshot

Axis	Classification
Stage	Pre-Seed
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	Latin America
Growth Profile	Venture Scale
Founding Team	Other
Funding	Undisclosed

How the Company Got Here

The company's founding story centers on a scientific ambition to reshape the understanding of prebiotic fibers [Crunchbase]. Future Biome was incorporated in 2022, founded by a team described as scientists and entrepreneurs [LinkedIn]. The company's CEO and founder is Soledad Gurovic, with Martín Larré also identified as a founder or key operator [CB Insights] [Perplexity Sonar Pro Brief].

Key operational milestones include winning the FoodTech World Cup in 2025 [Uruguay XXI, 2025]. The company's primary commercial signal was its pursuit of B2B licensing partnerships and the development of prebiotic fibers intended as food ingredients [F6S].

The company has ceased operations [Perplexity Sonar Pro Brief]. This marks the end of the company's venture timeline, which included securing investment from firms like Big Idea Ventures, LvlUp Ventures, and GRID Exponential [GreyB] [Crunchbase].

Data Accuracy: YELLOW -- Founder names and operational status are cited, but key details like headquarters location and full founding team are not publicly corroborated.

Product and Technology

The core proposition was a platform for developing precision fungal prebiotics. The company's public descriptions focused on a two-part system: a proprietary library of fungal strains engineered via precision fermentation, and an AI-driven personalization layer designed to match specific prebiotic formulations to individual gut microbiomes [Crunchbase] [GRIDX].

Key product surfaces included:

• Precision fermentation platform. The company claimed to produce fiber-rich mushroom components through fermentation [Vevolution] [CB Insights].
• AI efficacy prediction. A central claim was a customized platform using an artificial intelligence model to predict the effectiveness of a prebiotic from an individual's gut microbiota enzyme profile [GRIDX].
• B2B ingredient and partnership model. The intended commercial output was prebiotic fibers to be delivered as food ingredients or as part of precision nutrition offerings [BIO International Convention, 2026].

Data Accuracy: YELLOW -- Product claims are consistent across multiple startup databases, but lack independent technical validation or detailed public demos.

Where the Demand Sits

The market for microbiome-targeting therapeutics and functional ingredients is expanding toward a more targeted, data-driven approach. According to a 2026 report from BioPharma Dive, the global microbiome therapeutics market was projected to reach approximately $1.5 billion by 2030 [BioPharma Dive, 2026].

Demand is anchored in the growing clinical and consumer recognition of the gut microbiome's role in systemic health. Key drivers include the rising global prevalence of inflammatory bowel diseases (IBD) and other immune-mediated conditions [BioPharma Dive, 2026]. The company's stated B2B focus on food supplement companies and the pharma industry aligned with these channels [BIO International Convention, 2026].

Regulatory pathways present a defining force. While food ingredients may follow Generally Recognized as Safe (GRAS) designations, positioning products for therapeutic claims requires navigating clinical trial protocols. The macro environment for early-stage biotech funding, particularly following the downturn noted in 2025-2026, adds a layer of market risk [BioSpace, 2026].

Data Accuracy: YELLOW -- Market sizing is inferred from an analogous sector report; specific TAM for the company's niche is not publicly confirmed.

Competitive Landscape

Future Biome's competitive positioning was defined by its focus on a novel, fungi-based source for precision prebiotics. Segmenting the competitive map reveals a multi-layered landscape. The company faced competition from incumbent ingredient suppliers like DuPont and Kerry Group, which produce established, non-personalized prebiotic fibers [CB Insights]. More direct challengers would have been other precision nutrition biotechs. A significant adjacent substitute is the entire category of pharmaceutical anti-inflammatory drugs.

The company's primary edge was its early technical focus on the fungal microbiome and its AI-driven prediction platform. The defensibility of this edge would have hinged on proprietary fungal strains, fermentation processes, and the predictive algorithms [GRIDX] [BIO International Convention, 2026]. The company's participation in and victory at the FoodTech World Cup 2025 provided reputational capital.

Data Accuracy: ORANGE -- Competitive analysis is inferred from the company's stated positioning and general market structure due to a lack of named, public competitors in sources.

Opportunity

The headline opportunity was to become the precision prebiotic ingredient supplier for a generation of consumer health and pharmaceutical products. This outcome was reachable through a convergence of cited capabilities: a platform that analyzes individual enzyme profiles to predict efficacy [GRIDX], a production method using precision fermentation [Vevolution], and a stated B2B focus [BIO International Convention, 2026].

Scenario	What happens	Catalyst	Why it's plausible
Ingredient Licensing	The company's fungal fibers become a standard additive in functional foods and over-the-counter supplements.	A flagship partnership with a major consumer packaged goods (CPG) company or supplement brand.	The product was described as being delivered as food ingredients for the food industry [Perplexity Sonar Pro Brief].
Clinical Pipeline	The platform identifies a specific fungal strain with a pronounced, clinically-validated effect on an inflammatory condition.	Successful completion of a Phase I or II clinical trial demonstrating efficacy.	The company's core claim was developing prebiotics to combat inflammation with predictable efficacy [Crunchbase].

Data Accuracy: YELLOW -- Opportunity analysis is based on cited company claims and market comparables; the cessation of operations introduces significant uncertainty regarding the feasibility of these paths.

Sources

1. [Crunchbase] Future Biome - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/future-biome
2. [LinkedIn] Future Biome | LinkedIn | https://www.linkedin.com/company/future-biome
3. [GRIDX] Future Biome - GRIDX | https://www.gridexponential.com/startups/future-biome
4. [BIO International Convention, 2026] Future Biome - BIO International Convention | https://www.bio.org/events/bio-international-convention/exhibitor-directory/00892012
5. [CB Insights] Future Biome - Products, Competitors, Financials, Employees, Headquarters Locations | https://www.cbinsights.com/company/future-biome
6. [Perplexity Sonar Pro Brief] Perplexity Sonar Pro Brief |
7. [Uruguay XXI, 2025] Uruguay XXI Report on FoodTech World Cup 2025 |
8. [F6S] Future Biome - Startup profile - Investment data - Vevolution | https://www.vevolution.com/organisations/future-biome
9. [GreyB] Future Biome - GreyB | https://www.greyb.com/startups/future-biome/
10. [Vevolution] Future Biome - Startup profile - Investment data - Vevolution | https://www.vevolution.com/organisations/future-biome
11. [BioPharma Dive, 2026] Flagship-backed microbiome biotech Evelo to shut down | https://www.biopharmadive.com/news/evelo-close-layoffs-shut-flagship-microbiome/700618
12. [BioSpace, 2026] 6 biotechs that called it quits in Q1 - BioSpace | https://www.biospace.com/job-trends/6-biotechs-that-called-it-quits-in-q1